With the exception of critical cases, during the coronavirus pandemic the FDA mostly halted the inspections of overseas drug manufacturing sites. Now, long after they have resumed, the FDA is still very much behind schedule. In 2022, the agency only inspected 6 percent of overseas facilities, according to an investigation from ProPublica.
Read the full post on Becker's Hospital Review - Healthcare News
